Sobi Med - AltuvOct

Prophylaxis is not sufficient to prevent joint bleeds in haemophilia¹

Despite significant advances in treatment, opportunities remain to improve the lives of those living with haemophilia¹

A 12-month observational study of patients with severe haemophilia who received regular prophylaxis revealed that:¹

Explore adults’ challenges

How can we protect children from future complications of haemophilia A?²

Early initiation of prophylaxis is critical to prevent joint disease²

The same study also showed:²

Explore children’s challenges

This content is focused on treatment diagnosis, disease management and its challenges. There is no intent to connect it with ALTUVOCT^® data and its potential use.

1. Wilkins RA, et al. BMJ Open 2022;12; DOI:10.1136/bmjopen-2021-052358.
2. Srivastava A, et al. Haemophilia 2020;26:1–1581.

ALTUVOCT^® may prevent bleeds in haemophilia A^1-3

ALTUVOCT^® is a first-in-class high-sustained FVIII replacement therapy indicated in all age groups for the treatment and prophylaxis of bleeding in patients with haemophilia A¹

ALTUVOCT^® is powered by innovative bioengineering technology, extending half-life for 4x longer than SHL FVIII therapies and 3x longer than EHL FVIII therapies.^2,4 As the first and only approved haemophilia treatment that decouples FVIII from VWF, it provides the opportunity to overcome the VWF-imposed half-life ceiling.² It can sustain FVIII levels above 40 IU/dL for around 4 days in adults. For patients, this means they can stay in the non-haemophilia range for most of the week, helping to protect them from bleeds.^2,3,5,6

Explore more about how ALTUVOCT^® works

WITH ONCE-WEEKLY, FIXED-DOSE ALTUVOCT^®, YOU CAN:

Sustain FVIII levels in the non-haemophilia range, FVIII: >40 IU/dL for ~4 days in adults^*2,5 and for up to 3 days in paediatric patients^†3,6
Harness the physiological benefits of FVIII to its full potential^‡2,4
Deliver predictable protection against bleeds^§2,3
Shield patients from joint damage and pain^¶2,7
Simplify treatment with once-weekly fixed dosing and the reliability of monotherapy^**1

Explore ALTUVOCT^®’s efficacy

^*	Trough level of 15 IU/dL at day 7.²
^†	Mean trough level at 7 days after dose was 13.7 IU/dL at steady state.⁶
^‡	ALTUVOCT^® comprises a single rFVIII protein fused to 3 components that extend half-life.^2,4
^§	Includes spontaneous bleeds and joint bleeds in adults, and spontaneous bleeds and joint bleeds in paediatric patients.^2,3
^¶	In XTEND-1, 72% of adults had 0 joint bleeds and 100% of target joints resolved (n=45) on ALTUVOCT^® treatment.² In XTEND-1, there was a 0.21 (1.20) mean reduction (SD) in PROMIS pain intensity score from baseline to Week 52.² In XTEND-Kids, there was a 0.62 (2.52) mean reduction (SD) in PROMIS pain intensity score from baseline to Week 52.⁷
^**	The recommended dosing for routine prophylaxis for adult and paediatric patients is 50 IU/kg of ALTUVOCT^® administered once weekly. ALTUVOCT^® may also be used for resolution of bleeds and bleed protection during surgery.¹

EHL, extended half-life; FVIII, factor VIII; rFVIII, recombinant FVIII; SD, standard deviation; SHL, standard half-life.

ALTUVOCT^®. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/altuvoct-epar-product-information_en.pdf. Accessed December 2024.
von Drygalski A, et al. N Engl J Med 2023;388(4):310–318.
Malec L, et al. N Engl J Med 2024;391:235-46.
Dargaud Y, et al. Haematologica 2024. DOI:10.3324/haematol.2023.284498.
Srivastava A, et al. Haemophilia 2020;26(6):1–158.
Peyvandi F, et al. Blood 2023;142(Supplement 1):506-508.
Carcao M, et al. Quality of life in children with haemophilia A: Phase 3 XTEND-Kids study of efanesoctocog alfa. EAHAD. 6–9 February 2024. Frankfurt, Germany.

Unmet Needs in Haemophilia A: Addressing the Gaps in Care

Prophylaxis is not sufficient to prevent joint bleeds in haemophilia1

How can we protect children from future complications of haemophilia A?2

ALTUVOCT® may prevent bleeds in haemophilia A1-3

Prophylaxis is not sufficient to prevent joint bleeds in haemophilia¹

How can we protect children from future complications of haemophilia A?²

ALTUVOCT^® may prevent bleeds in haemophilia A^1-3